momelotinib dihydrochloride

momelotinib dihydrochloride (OJJAARA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

OJJAARA is a marketed brand name for momelotinib dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

momelotinib dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.